Thyroid
25 cases on levothyroxine dosing and TSH targets, hyperthyroidism therapy choices, thyroid nodules and cancer, and thyroid disease in pregnancy and critical illness — choose a case below to open its full multi-voice debate.
A 78-year-old woman's TSH has climbed twice, mildly, and her thyroid antibodies are positive. The disagreement isn't whether her thyroid is drifting — it's whether a documented trajectory and a known risk marker earn treatment before a textbook threshold is reached.
A choir teacher's thyroid labs have been normal for a year, and she still can't keep pace with her own rehearsals. The disagreement isn't whether her labs are adequate — it's whether a normal number settles the question of whether her hormone replacement actually is.
An 81-year-old man found unresponsive and profoundly hypothermic has myxedema coma, a diagnosis with a real mortality rate and almost no randomized evidence behind its treatment. The disagreement is whether to load T3 alongside T4 in a heart that may not tolerate either drug's full effect.
A man's levothyroxine dose has nearly tripled over three years without his TSH ever normalizing. The disagreement is whether to keep adjusting the dose and its timing, or stop and formally investigate why his gut isn't absorbing it.
A pregnant woman's free T4 is low but her TSH is entirely normal — a pattern the leading trial evidence says not to treat, and the leading observational data says to worry about. The disagreement is whether to treat a finding the randomized evidence has already tested and found didn't help.
A woman with a thyroid removed for cancer just found out she's pregnant. The disagreement isn't whether her levothyroxine needs to go up — every voice agrees it does — it's whether a fixed rule-of-thumb increase fits a patient with no thyroid tissue left to help her at all.
A stable hypothyroid patient's pharmacy switched her levothyroxine manufacturer without telling her, and two weeks later she says she doesn't feel like herself. The disagreement is how seriously to take a symptom report that arrives suspiciously well-timed to a label change nobody clinically intended.
Two women with Graves' disease are both weighing the antithyroid-drug trial against definitive therapy. What actually separates them isn't which one wants children — it's that one has a reasonable first-course prognosis ahead of her, and the other has already watched a full course fail.
A pregnant woman on propylthiouracil is approaching the point where guidelines say to switch to methimazole. The disagreement is whether to make that switch on schedule in a patient who is stable, or protect her stability at the cost of prolonging a drug with its own accumulating risk.
A newly diagnosed Graves' patient is starting antithyroid drug therapy, and two clinicians who agree on the drug disagree on the strategy — a fixed higher dose kept stable with added levothyroxine, or a lower dose continuously adjusted down as her labs improve.
A man on long-term amiodarone has become thyrotoxic, and his imaging can't cleanly separate the two mechanisms that cause it. The disagreement is whether to commit to one drug class, the other, or both at once in a heart too fragile to wait for certainty.
An 82-year-old woman with atrial fibrillation and osteoporosis has a mildly suppressed TSH and nothing else abnormal. The disagreement isn't whether a very low TSH deserves treatment — it's whether hers is low enough to count.
A young woman in thyroid storm needs four drug classes started urgently. The disagreement isn't which drugs — everyone agrees on all four — it's whether the sequence the textbooks insist on can be compressed when a patient is decompensating in front of you.
A new mother's thyroid has swung from mildly overactive to now genuinely underactive four months after delivery. The disagreement isn't about the hyperthyroid phase, which everyone already handled the same way — it's about how low, and how symptomatic, she needs to be before the hypothyroid phase earns treatment.
An 84-year-old man's family says he's just "slowing down," and his labs say he's profoundly hyperthyroid. The disagreement is how aggressively to treat a diagnosis whose biggest danger, in a heart his age, is the same one everyone almost missed.
A woman's eyes are visibly worsening from Graves' ophthalmopathy, and the newest, most effective drug for it also happens to carry real risk for a patient with her exact other diagnosis. The disagreement is whether the drug's power outweighs what it could do to her blood sugar.
A woman's thyroid cancer surgery went well, and the risk-stratification system built for exactly this moment gives a clear answer for how hard to suppress her TSH. The disagreement is what to do when her own risk score sits right at the boundary between two different answers.
A high-risk thyroid cancer survivor also has coronary artery disease and a history of atrial fibrillation. The disagreement isn't whether her cancer risk calls for aggressive TSH suppression — it's whether her heart can be asked to carry that target at all.
A man's mood has been stable on lithium for a decade, and his thyroid has just stopped keeping up. The disagreement is whether to treat the thyroid and keep the mood stabilizer that's working, or use this as the moment to move him off a drug he's needed for years.
A man on a kinase inhibitor for kidney cancer has developed new hypothyroidism mid-treatment. The disagreement isn't whether to treat it — it's whether ordinary levothyroxine dosing logic even applies to a thyroid being actively suppressed by the drug that's keeping his cancer controlled.
A woman on immunotherapy for melanoma has developed a thyroid immune-related adverse event severe enough to alarm her oncology team. The disagreement is whether her symptoms cross the line into needing to pause the treatment that's controlling her cancer.
A man three weeks into a critical illness has thyroid labs that look hypothyroid on paper. The disagreement is whether that pattern is his body adapting to survive a crisis, or a real hormone deficiency his body simply hasn't been able to correct on its own.
A man with a known multinodular goiter needs an urgent contrast CT. The disagreement is whether the iodine load he's about to receive is routine, or worth pre-treating for in a gland that has its own real reason to react to it.
A woman with undiagnosed, untreated Graves' disease needs an emergency appendectomy tonight. The disagreement is how to manage her real thyroid storm risk when there isn't time for the antithyroid-drug lead-in that would normally come first.
A woman's thyroid requirement has climbed steadily since her gastric bypass, and unlike an unexplained malabsorption workup, everyone already agrees on why. The disagreement is what to actually do about a cause that can't be reversed and won't fully resolve with a bigger pill.